PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Daniel Edelman with NCI Set to Talk at Molecular Diagnostics Conference March 7-8, in Philadelphia - Daniel Edelman, Facility Head of the Clinical Molecular Profiling Core at NCI, will give a presentation on “The Clinical Molecular Profiling Core: A New Paradigm in Personalized Cancer Care at the National Cancer Institute”
Daniel Edelman with NCI Set to Talk at Molecular Diagnostics Conference March 7-8, in Philadelphia

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2011/01/17 - Daniel Edelman, Facility Head of the Clinical Molecular Profiling Core at NCI, will give a presentation on “The Clinical Molecular Profiling Core: A New Paradigm in Personalized Cancer Care at the National Cancer Institute”.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

In this new age of targeted and personalized therapies, oncologists have become acutely aware that each patient and their associated tumor have their own characteristic biological properties; matching the correct treatment to the right patient and tumor appears increasingly important. Because genetic and epigenetic changes are fundamental to cancer pathogenesis, the Clinical Molecular Profiling Core (CMPC) focuses primarily on genomic technologies. Core scientific staff collaborates with clinical investigators to optimize study design in such matters as specimen type and assay selection, and support data analysis and interpretation. Importantly, the CMPC is also CLIA compliant enabling swift translation of research findings to the clinic and the flexibility to meet the unique clinical needs of NCI investigators.

Daniel Edelman earned his MS in Applied Molecular Biology at the University of MD Baltimore County in 1993 and went on to work as a research associate at the VA Medical Center investigating prion diseases under Dr. Bob Rohwer. From there he became a founding member (1994) of the Molecular Diagnostics Laboratory in the University of MD Medical Center under Dr. Sandy Stass where he helped the nascent lab pass two CAP inspections. Dan received his PhD in Medical Pathology in 2005 and after a short post-doc, moved over to the FDA and worked as a scientific reviewer in the OIVD/CDRH under Dr. Sally Hojvat in the Division of Microbiology Devices. For the last four years Dan has been the facility head of the Clinical Molecular Profiling Core under Dr. Paul Meltzer in the Genetics Branch of the Center for Cancer Research, NCI.

Come and join the discussion at GTCbio's Molecular Diagnostics Conference to be held in Philadelphia, PA on March 7-8, 2011. Network with colleagues in academia, industry, and healthcare to share and learn about the latest technologies and novel discoveries in the diagnostics field. Gain insight into the issues and challenges facing the healthcare industry and hear success stories from industry leaders.

Presenting organizations include Merck, Genentech, Illumina, Quest Diagnostics, On-Q-Ity, OncoVista, Caprion Proteomics and other leaders in the diagnostics industry.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Daniel Edelman with NCI Set to Talk at Molecular Diagnostics Conference March 7-8, in Philadelphia

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)